Semaglutide is FDA-approved as a prescription medicine, but its labeling bars certain people outright and tells prescribers to use real caution in several more. The bright lines fall into two groups: absolute contraindications that disqualify a patient regardless of how much they might benefit, and relative cautions where the decision turns on the individual clinical picture.
Per FDA labeling, semaglutide is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 and in those with prior serious hypersensitivity to the drug, while pregnancy, breastfeeding, type 1 diabetes, and diabetic ketoacidosis fall outside its approved use.
This contraindication rests on a specific carcinogenicity signal rather than a theoretical worry. The drug carries a boxed warning because two-year rodent studies tied it to thyroid tumors arising from the same cells that medullary thyroid carcinoma comes from, and human relevance could not be ruled out.
The labeling treats both a personal and a family history of medullary thyroid carcinoma or MEN2 as an absolute contraindication, carried in a boxed warning, because GLP-1 receptor agonists produced dose-dependent thyroid C-cell tumors in two-year rodent studies and the human risk cannot be excluded.
A documented serious reaction is an absolute bar, not a relative caution that a prescriber can weigh away. The record describes anaphylaxis and angioedema, both medical emergencies, and sensitivity can trace to either the active molecule or an inactive formulation ingredient.
Anyone with a prior serious hypersensitivity reaction, including anaphylaxis or angioedema, to semaglutide or any component of its formulation has an absolute contraindication and must not receive the drug again.
A prior history of pancreatitis sits as a serious caution rather than a hard contraindication, and the call comes down to clinical judgment. Acute pancreatitis has been reported in patients on GLP-1 receptor agonists, and although a definitive causal link stays debated, the signal is strong enough that the label tells prescribers to weigh it carefully.
A history of pancreatitis is a serious caution rather than an absolute contraindication, and because semaglutide was never studied in patients with prior pancreatitis, many clinicians avoid it or choose an alternative therapy and stop the drug promptly if pancreatitis is suspected.
The caution here follows directly from how the drug works. Semaglutide deliberately slows gastric emptying to blunt appetite and lower glucose, but in someone whose motility is already impaired, that mechanism compounds the existing problem instead of helping.
Because semaglutide deliberately slows gastric emptying and was not adequately studied in severe gastrointestinal disease such as severe gastroparesis, adding it to already-impaired motility can intensify nausea, vomiting, and dehydration and often tips the decision toward an alternative therapy.
The record is direct: semaglutide should not be used during pregnancy. Animal reproduction studies showed embryofetal death, structural abnormalities, and growth alterations at clinically relevant exposures, and with no adequate human data the potential fetal risk outweighs any benefit of continuing therapy.
The labeling advises against semaglutide in pregnancy and breastfeeding and, because of its roughly one-week half-life, recommends discontinuing it at least two months before a planned pregnancy so the drug clears before conception.
Semaglutide cannot replace insulin because its mechanism needs a working endogenous insulin response to begin with. As a GLP-1 receptor agonist it enhances glucose-dependent insulin secretion from pancreatic beta cells, which only helps when those cells can still produce insulin. In type 1 diabetes autoimmune attack has destroyed them, so there is little or nothing for the drug to amplify.
Semaglutide is approved only as an adjunct in type 2 diabetes and must never replace insulin in type 1 diabetes or treat diabetic ketoacidosis, because its glucose-dependent mechanism requires functioning beta cells and cannot supply the insulin an insulin-dependent patient needs.
On its own semaglutide rarely causes low blood sugar, because its insulin-stimulating effect is glucose-dependent and tapers off as levels normalize. The risk changes sharply when it is paired with agents that lower glucose regardless of the current level.
Because insulin and sulfonylureas lower blood glucose independent of its current level, combining either with semaglutide raises hypoglycemia risk, so prescribers frequently reduce the companion drug's dose when semaglutide is added.
Because semaglutide slows the rate at which the stomach empties into the small intestine, it can shift how and when other oral medications are absorbed. Most oral drugs are taken up in the small intestine, so a slower handoff can blunt a co-administered drug's peak concentration or shift its timing even when the total amount absorbed stays similar.
Semaglutide's delayed gastric emptying can blunt or shift the absorption peak of co-administered oral drugs, an interaction considered modest and manageable for most medications, though it warrants attention for narrow-therapeutic-index drugs.
Several conditions do not bar semaglutide outright but call for extra caution and closer monitoring. The common thread is that rapid metabolic change or GI side effects can destabilize an already-vulnerable system, so these patients are screened and watched more closely rather than excluded.
Diabetic retinopathy, severe kidney impairment, and significant hepatic impairment do not contraindicate semaglutide but warrant baseline assessment, closer monitoring, and slower titration, because rapid glucose lowering can transiently worsen retinopathy and GI-driven dehydration can precipitate acute kidney injury.
Educational use only. This article describes what the published scientific and clinical literature reports about Semaglutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
